CHOLOVUE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Aug 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHOLOVUE is an injectable diagnostic agent developed by Bracco, approved in 1981. The specific indication and mechanism of action are not publicly documented in available data. Based on the brand name and route, it likely functions as an imaging or diagnostic aid administered by injection.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a contracting team focused on lifecycle management rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CHOLOVUE offers limited career growth opportunities given its mature, LOE-approaching lifecycle. Roles available are primarily in field sales, commercial operations, and lifecycle management rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on CHOLOVUE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.